Finanzen von Zhengye Biotechnology Holding Ltd (ZYBT)ZYBTZhengye Biotechnology Holding Ltd

Evaluating the bottom line, Zhengye Biotechnology Holding Ltd maintains a gross margin of 20.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -60.59%, while the net margin is -71.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZYBT converts its operational activities into shareholder value.

In the context of the broader market, ZYBT competes directly with industry leaders such as TIL and TCRX. With a market capitalization of $51.42M, it holds a significant position in the sector. When comparing efficiency, ZYBT's gross margin of 20.51% stands against TIL's N/A and TCRX's 100.00%. Such benchmarking helps identify whether Zhengye Biotechnology Holding Ltd is trading at a premium or discount relative to its financial performance.

The financial performance shows concerning trends, with a gross margin projected to decrease from 48.99% in Q4 2024 to 20.51% in Q4 2025, alongside a net margin that is expected to worsen from 7.23% to -71.30% over the same period. This indicates deteriorating profitability.